Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Return on Capital Employed (ROCE) | 6.8% | 11.7% | 10.5% | 8.8% | 10.0% | 8.0% | 6.9% | 7.6% | 8.3% | 8.9% | 9.4% | 7.3% | 10.0% | 9.7% | 13.8% | 14.4% | 15.6% | 25.8% | 21.3% | 17.7% |
Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.
As of today, Microsoft Corp's last 12-month Return on Capital Employed (ROCE) is 15.6%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Return on Capital Employed (ROCE) for West Pharmaceutical Services, Inc. have been 19.3% over the past three years, and 18.6% over the past five years.
As of today, West Pharmaceutical Services, Inc.'s Return on Capital Employed (ROCE) is 15.6%, which is higher than industry median of (0.8%). It indicates that West Pharmaceutical Services, Inc.'s Return on Capital Employed (ROCE) is Good.